Physician profile
Ralph Gousse
NPI 1457316341
$9,915.12
in general payments reported to CMS, 2019-2025
60 companies · $2,849 in 2025
The $2,849 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $932 · 2020: $362 · 2021: $474 · 2022: $1,365 · 2023: $1,963 · 2024: $1,970 · 2025: $2,849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,571 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,570.96 |
| Education | $210.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $928.46 | 2019-2025 | |
| Pfizer INC. | $773.78 | 2019-2025 | |
| Celgene Corporation | $731.43 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Janssen Biotech, INC. | $582.19 | 2019-2025 | Rybrevant |
| Gilead Sciences, INC. | $564.47 | 2019-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $540.33 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Genentech USA, INC. | $393.69 | 2019-2025 | Polivy, Tecentriq, Lunsumio |
| Astrazeneca Pharmaceuticals LP | $336.13 | 2022-2025 | Enhertu |
| Astellas Pharma US INC | $322.33 | 2020-2025 | Vyloy, Xtandi, Padcev |
| Daiichi Sankyo INC. | $318.15 | 2023-2025 | Enhertu, Vanflyta, Datroway |
| Kite Pharma, INC. | $316.64 | 2020-2025 | Yescarta |
| Merck Sharp & Dohme LLC | $287.86 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Seagen INC. | $265.91 | 2020-2025 | Adcetris, Padcev, Tukysa |
| Karyopharm Therapeutics INC. | $251.57 | 2020-2025 | Xpovio |
| Abbvie INC. | $219.64 | 2022-2025 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $214.12 | 2019-2025 | Monjuvi, Zynyz, Jakafi |
| Amgen INC. | $209.70 | 2019-2023 | Lumakras, Xgeva, Nplate |
| Exelixis INC. | $207.89 | 2019-2025 | Cabometyx |
| Apellis Pharmaceuticals, INC. | $204.96 | 2022-2023 | Empaveli |
| Pharmacyclics LLC, An Abbvie Company | $200.53 | 2021-2023 | Imbruvica |
| Glaxosmithkline, LLC. | $149.75 | 2022-2025 | Ojjaara, Blenrep |
| Jazz Pharmaceuticals INC. | $139.51 | 2021-2024 | |
| Eisai INC. | $123.12 | 2019-2025 | |
| Array Biopharma INC | $122.42 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Coherus Oncology, INC. | $113.06 | 2022-2025 | Loqtorzi |
| Rigel Pharmaceuticals, INC. | $92.26 | 2019-2024 | Rezlidhia, Tavalisse |
| Beigene USA, INC. | $84.95 | 2022-2024 | Brukinsa |
| Emd Serono, INC. | $83.98 | 2022-2024 | Bavencio |
| Adc Therapeutics America, INC. | $70.11 | 2024-2025 | |
| Tersera Therapeutics LLC | $69.88 | 2023-2025 | Zoladex |
| Pharmaessentia USA Corporation | $69.03 | 2023-2025 | Besremi |
| Beone Medicines USA, INC. | $62.13 | 2025 | Brukinsa |
| Blueprint Medicines Corporation | $61.04 | 2024-2025 | Ayvakit |
| Geron Corporation | $58.93 | 2025 | Rytelo |
| Taiho Oncology, INC. | $58.68 | 2021-2025 | |
| G1 Therapeutics, INC. | $55.68 | 2022-2023 | Cosela |
| Sobi, INC | $53.17 | 2024 | |
| Dendreon Pharmaceuticals LLC | $50.76 | 2024-2025 | Provenge |
| Global Blood Therapeutics, INC. | $47.10 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.75 | 2025 | Fruzaqla, Iclusig |
| Mirati Therapeutics, INC. | $44.57 | 2023 | Krazati |
| Genzyme Corporation | $36.02 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $33.66 | 2024-2025 | |
| Immunocore Limited | $32.81 | 2025 | Kimmtrak |
| Kyowa Kirin, INC. | $31.90 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $27.63 | 2019 | |
| Aurobindo Pharma USA, INC. | $25.66 | 2019 | |
| Foundation Medicine, INC. | $24.28 | 2019 | |
| Deciphera Pharmaceuticals INC. | $22.26 | 2025 | Romvimza, Qinlock |
| Pharmacosmos Therapeutics INC. | $18.42 | 2024 | Cosela |
| Tg Therapeutics, INC. | $17.98 | 2021 | |
| Cti Biopharma Corp. | $17.20 | 2022 | |
| Morphosys, US INC. | $16.01 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.17 | 2022 | |
| Syndax Pharmaceuticals, INC. | $14.83 | 2025 | |
| Csl Behring | $14.60 | 2024 | Idelvion, Afstyla |
| Verastem, INC. | $14.40 | 2019 | |
| Stemline Therapeutics INC. | $13.92 | 2023 | Orserdu |
| Acrotech Biopharma INC. | $11.97 | 2022 | |
| Veracyte, INC. | $0.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Gousse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.